Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alexion Pharmaceuticals Inc. ALXN

Healthcare Biotechnology
Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS... see more

Recent & Breaking News (NDAQ:ALXN)

Alexion Reports Second Quarter 2017 Results

Business Wire July 27, 2017

Robbins Arroyo LLP Is Investigating the Officers and Directors of Alexion Pharmaceuticals, Inc. (ALXN) on Behalf of Shareholders

Business Wire July 19, 2017

The Market In 5 Minutes

Benzinga.com  July 7, 2017

Exclusive: Alexion Responds To Government Probe

Benzinga.com  July 6, 2017

Alexion parvient à une entente de financement avec NICE et NHS England portant sur Strensiq® (asfotase alfa) destiné aux patients atteints d'hypophosphatasie apparue dans l'enfance

Business Wire July 5, 2017

Alexion Reaches Funding Agreement with NICE and NHS England for Strensiq® (asfotase alfa) for Patients with Pediatric-onset Hypophosphatasia (HPP)

Business Wire July 5, 2017

Alexion Receives Positive CHMP Opinion for Soliris® (Eculizumab) for the Treatment of Patients with Refractory Generalized Myasthenia Gravis (gMG) in the European Union

Business Wire June 23, 2017

C-Suite Shake Up: How Paul Clancy Jumping Ship Affects Alexion, Biogen

Benzinga.com  June 15, 2017

Alexion's New CFO Continues To Shore Up Investor Concerns

Benzinga.com  June 14, 2017

Alexion Names Paul Clancy Chief Financial Officer

Business Wire June 13, 2017

Technical Snapshots for These Biotech Stocks -- Gilead Sciences, Aurinia Pharma, Esperion Therapeutics, and Alexion Pharma

PR Newswire June 8, 2017

Alexion Announces Additions to Executive Leadership Team

Business Wire June 1, 2017

Lifshitz & Miller LLP Announces Investigation of Akari Therapeutics, Plc, Alexion Pharmaceuticals, Inc., Amgen Inc., Cel-Sci Corp., Dick's Sporting Goods, Inc., Eco Science Solutions, Inc., Intra-Cellular Therapies, Inc. and Twilio Inc.

PR Newswire May 30, 2017

Alexion to Present at Upcoming Investor Conferences

Business Wire May 30, 2017

The Market In 5 Minutes

Benzinga.com  May 24, 2017

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Orbotech Ltd. (ORBK)

PR Newswire May 23, 2017

Mid-Day Market Update: Kirkland's Drops After Weak Q1 Results; Helios and Matheson Analytics Shares Surge

Benzinga.com  May 23, 2017

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Orbotech Ltd. - ORBK

PR Newswire May 23, 2017

Alexion Announces Executive Leadership Changes

Business Wire May 23, 2017

Glancy Prongay & Murray LLP Commences Investigation on Behalf of Alexion Pharmaceuticals, Inc. Investors

Business Wire May 18, 2017